Scholarlink

<p>Brain metastases from colorectal cancer are rare but carry a dismal prognosis. This study aimed to develop and externally validate a prognostic model for individualized survival prediction in affected patients. The model was constructed using a training cohort of 112 patients diagnosed with brain metastases after initial colorectal cancer treatment at our institution between 1985 and 2017, and validated in an external cohort of 114 patients referred for brain metastasis treatment between 1987 and 2017. A nomogram was developed incorporating five variables: age, performance status assessed by the Karnofsky Performance Status scale, number of brain metastases, maximum size of brain lesions, and number of prior systemic chemotherapy regimens. In the training cohort, the median survival was 6.6&#xa0;months, with 1-year and 3-year survival rates of 29.0% and 7.2%. Poorer performance status, multiple metastases, and higher number of chemotherapy regimens were associated with worse prognosis. In the validation cohort, median survival was 5.8&#xa0;months, with 1-year and 3-year survival rates of 27.0% and 8.4%. Harrell’s concordance index was 0.70 for internal validation and 0.63 for external validation. This model may provide a clinically useful tool for individualized survival estimation in patients with brain metastases from colorectal cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development and validation of a prognostic nomogram for survival in patients with brain metastases from colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月6日

查看全文
  • Jun Imaizumi,
  • Dai Shida,
  • Narikazu Boku,
  • Hiroshi Igaki,
  • Yasuji Miyakita,
  • Issei Kitabayashi,
  • Yoshitaka Narita,
  • Jun Itami,
  • Atsuo Takashima,
  • Yukihide Kanemitsu

摘要

Brain metastases from colorectal cancer are rare but carry a dismal prognosis. This study aimed to develop and externally validate a prognostic model for individualized survival prediction in affected patients. The model was constructed using a training cohort of 112 patients diagnosed with brain metastases after initial colorectal cancer treatment at our institution between 1985 and 2017, and validated in an external cohort of 114 patients referred for brain metastasis treatment between 1987 and 2017. A nomogram was developed incorporating five variables: age, performance status assessed by the Karnofsky Performance Status scale, number of brain metastases, maximum size of brain lesions, and number of prior systemic chemotherapy regimens. In the training cohort, the median survival was 6.6 months, with 1-year and 3-year survival rates of 29.0% and 7.2%. Poorer performance status, multiple metastases, and higher number of chemotherapy regimens were associated with worse prognosis. In the validation cohort, median survival was 5.8 months, with 1-year and 3-year survival rates of 27.0% and 8.4%. Harrell’s concordance index was 0.70 for internal validation and 0.63 for external validation. This model may provide a clinically useful tool for individualized survival estimation in patients with brain metastases from colorectal cancer.